Developing the next generation of antimicrobial therapies

CARE CF 1 oral Lynovex clinical trial data published

Dec 29, 2020

NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF...

Just when we thought things were getting better…..

By Grant Ellis, Director NovaBiotics Ltd Back in October I quoted Sir Patrick Vallance, the government’s Chief Scientific Adviser saying that no vaccine for Covid was likely before the spring of 2021. We all now know that there are two vaccines that have been...

CARE CF 1 oral Lynovex clinical trial data published

NovaBiotics in the press

NovaBiotics featured in an article published in the Mail on Sunday on 27 December 2020 entitled “British scientists are engineering superbug-beating medications to fight off killer infections including MRSA.” See the full article by clicking Mail on Sunday Article 27...

As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation

To mark World Antimicrobial Awareness Week, Deborah O’Neil tells pharmaphorum why 2021 might be the year anti-infective drugs finally demonstrate their economic value. You can access full article here Pharmaphorum Article 18 Nov 2020

Why, in the current crisis we still need more effective, proven treatments for COVID-19

Grant Ellis – Director NovaBiotics Ltd The COVID-19 pandemic has now affected over 50m people worldwide, with over 1.25m reported deaths. This is why we should all welcome the announcements by both Pfizer and BioNTech and Moderna Inc. about the successful...

Appointment of Dr Malcolm Barratt-Johnson to the Board of NovaBiotics

ABERDEEN 10th NOVEMBER 2020. NovaBiotics, the anti-infectives and respiratory therapy Biotechnology Company announces the appointment of Dr Malcolm Barratt-Johnson to its Board as Non-Executive Director. Malcolm is a consultant pharmaceutical physician who has...

The truth about why we need this COVID-19 treatment right now!

By Grant Ellis, Director NovaBiotics Ltd On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will probably never disappear and a vaccine won't stop it completely. He also said that ministers and experts should...

NovaBiotics secures £1m funding for COVID 19 project

NovaBiotics secures £1 million in funding from Innovate UK to support clinical development of Nylexa for COVID-19 Aberdeen, 16 October 2020. NovaBiotics, the clinical stage antimicrobials drug discovery company, announces that it has secured £1 million in funding from...

OBE for NovaBiotics’ CEO in the Queen’s Birthday Honours List

NovaBiotics’ founder and Chief Executive Officer, Dr Deborah O’Neil FRSE, was amongst those recognised in the Queen’s 2020 Birthday Honours list. Deborah was made an Officer of the Most Excellent order of the British Empire (OBE) for services to biotechnology,...

“Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy” published today

NovaBiotics are delighted to announce that our latest publication is accessible from today. Teamwork focused on solutions to antimicrobial resistance with our collaborators - Marcelo Der Torossian Torres, University of Pennsylvania Cesar de la Fuente, University of...

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including NM002 (Nylexa®), an antibiotic potentiator for drug resistant bacterial infections including the secondary bacterial infections associated with COVID-19, NM001 (Lynovex®), an orphan drug candidate for cystic fibrosis (CF) and NP339, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. NP423 (Novarifyn®) is a bactericidal peptide for difficult to treat Gram negative and Gram positive bacteria and NP213 (Novexatin®), a potential step change therapy for onychomycosis.